Clinical Trials Logo

Nephrolithiasis, Uric Acid clinical trials

View clinical trials related to Nephrolithiasis, Uric Acid.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04370093 Recruiting - Clinical trials for Nephrolithiasis, Uric Acid

Pathogenesis of Uric Acid Nephrolithiasis: Role of Pioglitazone/Weight Loss

Start date: October 17, 2019
Phase: Phase 4
Study type: Interventional

The investigators will randomize overweight and obese iuan patients to Pio (45 mg/day, highest approved dose or placebo), WL (10% of body weight, following the established program used in the Diabetes Prevention Program), or Pio+WL. Participants will be evaluated at baseline and after 24 weeks of intervention while on a fixed metabolic diet to exclude the confounding effects of diet and perspiration. The primary endpoint will be change in upH, and multiple additional endpoints (serum, urine, imaging) will be assessed.